Transplantation is the ideal therapy for end stage heart and end stage kidney failure, but allograft survival and function remain suboptimal. This CTOT renewal application will build upon the findings resulting from the previous 4 years of studying biomarkers and mechanisms of injury in heart and kidney transplant recipients in an effort to develop therapies tailored to individual patients. The overriding clinical hypothesis is that specifically designed therapies guided by rationally chosen noninvasive immune monitoring will improve outcomes in heart and kidney transplant recipients. This hypothesis will be tested through 2 studies targeting 2 separate transplant populations. Study Concept 1 will test the hypothesis that the absence of anti-donor T cell memory will facilitate safe calcineurin inhibitor (CNI) elimination in nonsensitized, low risk recipients of kidney allografts. Recipients of living donor kidney allografts from 7 collaborating centers, without clinical acute rejection, donor-specific antibody or inflammation on protocol biopsy, and without evidence of anti-donor primed/memory T cells in their peripheral blood at 6 months will be randomized to tacrolimus elimination or remain on standard therapy. Renal function and histologic evidence of chronic injury at 24 months will be used as endpoints. The trial will be done within the established infrastructure built by us for the ongoing CTOT trials. The associated mechanistic studies will assess the impact of targeted anti- memory therapy including T cell depletion on the alloreactive effector T cell repertoire and will evaluate the molecular basis of allograft fibrosis in the presence or absence of tacrolimus. Study concept 2 will involve identifying heart transplant candidates at high risk for antibody mediated injury (high PRA) and performing a pilot study to determine the safety and efficacy of desensitization using a combination of B cell depletion (rituximab), IVIG plasmapheresis. The study will test the hypothesis that desensitization will lower PRA, diminish the waiting time to heart transplantation and result in acceptable 1 year graft survival and function. Patients will be enrolled from within a powerful consortium of 22 North American heart transplant centers that was developed for the ongoing heart transplantation CTOT05 study. Associated mechanistic studies will determine how the desensitization protocol impacts preformed alloreactive T and B cell immunity and will test the hypothesis that residual B and T cell immune memory with reactivity to donor antigens mediates post-transplant allograft injury. The proposed studies will address clinically relevant questions in kidney and heart transplantation and will provide novel information regardless of outcome.

Public Health Relevance

Kidney transplantation and heart transplantation are lifesaving treatments for organ failure, but the transplanted organs do not last indefinitely. The goals of the proposed work are 1) to test new approaches for improving transplant outcomes (making organs last longer), 2) to identify modifiable risk factors to improve outcomes and 3) determine why the heart or kidney transplants fail so as to design better treatments.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SV-I (M1))
Program Officer
Hayes, Deborah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Cravedi, Paolo; Manrique, Joaquin; Hanlon, Katherine E et al. (2014) Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol 25:2003-15
Mehrotra, Anita; Heeger, Peter S (2014) B cells and kidney transplantation: beyond antibodies. J Am Soc Nephrol 25:1373-4
Traitanon, Opas; Poggio, Emilio D; Fairchild, Robert L (2014) Molecular monitoring of alloimmune-mediated injury in kidney transplant patients. Curr Opin Nephrol Hypertens 23:625-30
Li, Lily; Lin, Marvin; Krassilnikova, Maria et al. (2014) Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS One 9:e109998
Valenzuela, Nicole M; McNamara, Jeffrey T; Reed, Elaine F (2014) Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 19:33-40
Chandraker, Anil; Strom, Terry B (2013) Transplantation: a new molecular approach to the diagnosis of acute rejection. Nat Rev Nephrol 9:631-2
Ashoor, I; Najafian, N; Korin, Y et al. (2013) Standardization and cross validation of alloreactive IFNýý ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 13:1871-9
Sigdel, Tara K; Sarwal, Minnie M (2013) Discovery and customized validation of antibody targets by protein arrays and indirect ELISA. Methods Mol Biol 1034:373-84
Hricik, D E; Nickerson, P; Formica, R N et al. (2013) Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 13:2634-44
Sigdel, Tara K; Sarwal, Minnie M (2013) Moving beyond HLA: a review of nHLA antibodies in organ transplantation. Hum Immunol 74:1486-90

Showing the most recent 10 out of 25 publications